Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

Pionyr raises $62M series B

December 15, 2017 4:04 AM UTC

On Dec. 13, Pionyr Immunotherapeutics Inc. (San Francisco, Calif.) raised $62 million in a series B round led by New Enterprise Associates. Fellow new investors Sofinnova Ventures and Vida Ventures also participated, as did existing investors OrbiMed, SV Health Investors, Osage University Partners and Mission Bay Ventures.

Since its founding in 2015, Pionyr has now raised a total of $72 million...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article